Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | CCR3 | P51677 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42218 | 0.92 | SIGMAR1 (0.61) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL10705671 | 0.88 | ALDH1A1 (0.59) | SIGMAR1LMNAPOLBKMT2A | |
| SCHEMBL5535229 | 0.88 | SIGMAR1 (0.59) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1111888 | 0.84 | DRD4 (0.53) | SIGMAR1DRD4 | |
| SCHEMBL1041303 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL8188324 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1415730 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL576868 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2489199 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL242970 | 0.84 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6410577-B1 | — | — | None | — | — | US | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| CN-117838699-A | Use of disubstituted purines for anti-inflammatory | 北京大学 | 2024-04-09 | — | — | CN | claimed |
| CN-117229268-A | Hydrazide-containing nuclear transport modulators and uses thereof | 卡尔约药物治疗公司 | 2023-12-15 | — | — | CN | claimed |
| CN-114478451-B | 6- (hydroxybenzyloxy) phthalein mannich base compound, preparation method and application thereof | 四川大学 | 2023-12-05 | — | — | CN | claimed |
| CN-117143028-A | Hydroxyphenyl pyridazine Mannich base compound, and preparation method and application thereof | 四川大学 | 2023-12-01 | — | — | CN | claimed |
| CN-110372672-B | Hydrazide-containing nuclear transport modulators and uses thereof | 卡尔约药物治疗公司 | 2023-09-29 | — | — | CN | claimed |
| CN-112300145-B | Tri-aromatic ring compound targeting STAT3 bifunctional phosphorylation site and application thereof | 上海宇耀生物科技有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-114805263-B | 3- (hydroxybenzyl) phthalide compound, preparation method and application thereof | 四川大学 | 2023-05-05 | — | — | CN | claimed |
| CN-114315689-B | Disulfanylphthalimide compound, preparation method and application thereof | 四川大学 | 2023-04-07 | — | — | CN | claimed |
| US-4342762-A | USEFUL AS TRANQUILIZERS, ANALGESICS, ANTIEPILEPTIC AGENTS, AND AS A TREATMENT FOR PARKINSON'S DISEASE | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1982-08-03 | — | — | US | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| US-4324786-A | SEDATIVES, ANALGESICS, ANTIINFLAMMATORY, ANTIPYRETIC | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1982-04-13 | — | — | US | claimed |
| US-4322418-A | PROMOTION OF BLOOD CIRCULATION | C. H. BOEHRINGER SOHN (DE) | 1982-03-30 | — | — | US | claimed |
| EP-0039051-A2 | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1981-11-04 | — | — | EP | claimed |
| US-4279905-A | GASTROINTESTINAL DISORDERS | KALI-CHEMIE PHARMA GMBH (DE) | 1981-07-21 | — | — | US | claimed |
| EP-0025109-A2 | 1-Benzoxepin-5(2H)-one derivatives and their salts, and processes for their preparation | Kali-Chemie Pharma GmbH (DE) | 1981-03-18 | — | — | EP | claimed |
| US-4128643-A | 4-Quinazolinyl-guanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-12-05 | — | — | US | claimed |
| US-4059584-A | ANTIINFLAMMATORY | PFIZER (US) | 1977-11-22 | — | — | US | claimed |
| US-4002623-A | Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines | PFIZER INC. (US) | 1977-01-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | SIGMAR1 3525/4885MC4R 3880/4885DRD4 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.